An interventional study of BiPAP and HFNC in Ventilatory Failure, sponsored by OhioHealth. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-13.
Sponsored by OhioHealth · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Hypoventilation with a site in United States — 3 open to participants now, 4 under way, none of them phase 3. Hypoventilation · United States.
Among the 27 studies in Hypoventilation with a site in United States, this one is the 17th largest by enrollment of the 20 interventional ones that give a count, is one of 5 that started in 2020, is one of 19 with no phase, and was the 15th registered.
96 studies on the registry are indexed under Hypoventilation; 21 are open to participants now.
Browse Hypoventilation studies →3 of the 27 studies in Hypoventilation with a site in United States are open now. Recruiting first, the newest first:
NeurOptics Inc · Sites in United States
Ages 3–17 · Healthy volunteers
University of Colorado, Denver · Sites in United States
Ages 18–90
Ilya Khaytin · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 14 Hypoventilation studies recruiting now, 8 (57%) set no upper age limit and 5 (36%) stop at 75 or younger; 2 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 5 started in 2020.
This study's enrollment of 6 is below the median of 52 across 63 interventional studies indexed under Hypoventilation.
Median enrollment 62 across the 20 interventional studies, 30 across the 7 observational. Of the 19 that completed or were terminated, 10 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 27 have an industry lead sponsor. The 10 most frequent:
OhioHealth is the lead sponsor of 25 studies on the registry; none are open to participants now.
OhioHealth has 1 study filed under Hypoventilation — fewer than ten, so there is no comparison to draw.
1 of the studies in Hypoventilation with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07573150NeurOptics IncPupillometry in Identifying Risk of Postoperative Opioid-induced Respiratory Depression in Children Undergoing Tonsillectomy | 2027-04-30 |
Add it to your calendar (.ics) → With an account.
Among the 27 studies in Hypoventilation with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
At the time of weaning from mechanical ventilation, patients with heart and/or lung conditions will be given oxygen support with alternating bilevel positive airway pressure (BiPAP; oxygen via face mask) and heated high flow nasal cannula oxygen (HFNC; oxygen via nasal cannula) to see if this method reduces the likelihood of re-intubation.
It is clinically challenging to predict when patients can be successfully removed from mechanical ventilation (MV). Liberating high-risk patients such as the elderly and those with complex, chronic cardiac or pulmonary diseases from MV is particularly challenging.
Evidence from randomized trials and meta-analyses suggests that the type of postextubation supportive care provided, such as oxygen delivery via nose or mouth, may affect the risk of reintubation. However, it is unclear which of many possible postextubation management protocols results in the best patient outcomes, particularly for this subset of high-risk patients.
The purpose of this study is therefore to assess a standardized combined protocol of postextubation oxygen delivery consisting of early, alternating BiPAP with HFNC over 24 hours following extubation. BiPAP and HFNC are both currently provided to patients as standard of care, based on clinician judgement; however, the timing and nature of the methods are variable.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will be placed on alternating BiPAP and HFNC for 24 hours following extubation
Device: BiPAP · Device: HFNC
A historical control cohort will be composed of patients treated according to their physician's standard of care following removal from mechanical ventilation.
Bilevel Positive Airway Pressure (BiPAP) oxygen administration
Heated High Flow Nasal Cannula oxygen administration
Re-intubation Within 72 Hours
The number of patients who require re-intubation
Time frame: 72 hours following extubation
Re-intubation Within 1 Week
The number of patients who require re-intubation
Time frame: 1 week following extubation
Length of Stay
Hospital length of stay
Time frame: Through hospital discharge, an average of 10.9 ± 1.91 days
Ventilator Time
The total duration of time patients spend on a ventilator
Time frame: Through hospital discharge, an average of 10.9 ± 1.91 days
Mortality
The proportion of patients who expire during the hospital stay
Time frame: Through hospital discharge, an average of 10.9 ± 1.91 days
Adverse Event Rate
The proportion of patients experiencing an adverse event
Time frame: Through 1 week following extubation
30-day Readmission
The proportion of patients who require re-admission within 30 days of discharge
Time frame: 30 days following discharge
| Milestone | Experimental: Alternating BiPAP and HFNC | Historical Control: Standard of Care |
|---|---|---|
| Started | 4 | 0 |
| Completed | 3 | 0 |
| Not completed | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
The number of patients who require re-intubation
| participants | Experimental: Alternating BiPAP and HFNC | Historical Control: Standard of Care |
|---|---|---|
| Re-intubation Within 72 Hours | 0 | — |
The number of patients who require re-intubation
| participants | Experimental: Alternating BiPAP and HFNC | Historical Control: Standard of Care |
|---|---|---|
| Re-intubation Within 1 Week | 0 | — |
Hospital length of stay
| Days | Experimental: Alternating BiPAP and HFNC | Historical Control: Standard of Care |
|---|---|---|
| Length of Stay | 10.9 ± 1.91 | — |
The total duration of time patients spend on a ventilator
| Days | Experimental: Alternating BiPAP and HFNC | Historical Control: Standard of Care |
|---|---|---|
| Ventilator Time | 3.5 ± 1.33 | — |
The proportion of patients who expire during the hospital stay
| Participants | Experimental: Alternating BiPAP and HFNC | Historical Control: Standard of Care |
|---|---|---|
| Mortality | 0 | — |
The proportion of patients experiencing an adverse event
| Participants | Experimental: Alternating BiPAP and HFNC | Historical Control: Standard of Care |
|---|---|---|
| Adverse Event Rate | 1 | — |
The proportion of patients who require re-admission within 30 days of discharge
| Participants | Experimental: Alternating BiPAP and HFNC | Historical Control: Standard of Care |
|---|---|---|
| 30-day Readmission | 0 | — |
Collected over Through hospital discharge, and average of 10.9 days.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Experimental: Alternating BiPAP and HFNC | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) |
| Historical Control: Standard of Care | — | — | — |
| Event | Experimental: Alternating BiPAP and HFNC | Historical Control: Standard of Care |
|---|---|---|
| VomitingGastrointestinal disorders | 1/3 | — |
Because the prospective group was terminated, no data collection for the historical control was collected.
| Age, Categorical(Participants) | Experimental: Alternating BiPAP and HFNC | Historical Control: Standard of Care | Total |
|---|---|---|---|
| <=18 years | 0 | — | 0 |
| Between 18 and 65 years | 1 | — | 1 |
| >=65 years | 2 | — | 2 |
| Sex: Female, Male(Participants) | Experimental: Alternating BiPAP and HFNC | Historical Control: Standard of Care | Total |
|---|---|---|---|
| Female | 2 | — | 2 |
| Male | 1 | — | 1 |
| Race (NIH/OMB)(Participants) | Experimental: Alternating BiPAP and HFNC | Historical Control: Standard of Care | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | — | 0 |
| Asian | 0 | — | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | — | 0 |
| Black or African American | 1 | — | 1 |
| White | 2 | — | 2 |
| More than one race | 0 | — | 0 |
| Unknown or Not Reported | 0 | — | 0 |
| Region of Enrollment(participants) | Experimental: Alternating BiPAP and HFNC | Historical Control: Standard of Care | Total |
|---|---|---|---|
| United States | 3 | — | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2020 to primary completion in Feb 2020, 0 months.
Results were first posted in Jan 2022, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
OhioHealth